Clinical trials: Pregnancy Loss
Recurrent Pregnancy Loss, Anxiety Disorders
Right Prefrontal Autonomic Mapping in Recurrent Pregnancy Loss With Comorbid Anxiety
Recurrent pregnancy loss is often accompanied by substantial anxiety and may also be associated with autonomic imbalance and increased long-term cardiovascular vulnerability.
- Trial name
- NCT06968026
- Testing
- repetitive transcranial magnetic stimulation(rTMS)
- Where
- 4 sites in China
- Volunteers
- 55 people
- Sponsor
- Shenyang Jinghua Hospital
Abortion; Attempted, Medical
Feasibility of a Self-performed Urinary Test for the Follow-up on Medical Abortion
This study was a national, longitudinal, prospective, observational survey, carried out in metropolitan France, with a sampling of 21 birth control centres.
- Trial name
- NCT02304835
- Where
- France
- Volunteers
- 322 people
- Sponsor
- Nordic Pharma SAS
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression
- Trial name
- NCT07446049
- Testing
- CVL237 tablets
- Volunteers
- 180 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Birth Defect, Spontaneous Abortions
Nplate® Pregnancy Exposure Registry
US study to estimate the prevalence at birth of major birth defects (ie, those that cause significant functional or cosmetic impairment, require surgery, or are life-limiting) in children born to mothers who have received Nplate®…
- Conditions
- Birth Defect, Spontaneous Abortions, Low Birth Weight
- Trial name
- NPER (NCT02090088)
- Testing
- Not applicable- observational study
- Volunteers
- 4 people
- Sponsor
- Amgen
Infertility, Recurrent Pregnancy Loss
Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis
We propose to perform a clinical randomized trial to evaluate the effect of blastocyst biopsy and whole chromosome analysis by Next Generation Sequencing (NGS) in comparison to standard Assisted Reproductive Technologies (ART)…
- Trial name
- NCT01946945
- Testing
- Next Generation Sequencing after Blastocyst biopsy
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Reprogenetics
Recurrent Miscarriage
Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage
The purpose of this clinical study is to demonstrate the shift from inflammatory cytokines to non-inflammatory cytokines in women suffering from habitual abortion treated with dydrogesterone (Duphaston).
- Trial name
- NCT00193674
- Testing
- Dydrogesterone
- Where
- 3 sites in Austria, Poland
- Volunteers
- 71 people
- Sponsor
- Abbott Products
Advanced Solid Tumor, CDKN2A
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
This is an open-label, single-arm, Phase 1b/2 study designed to evaluate the safety, tolerability, and preliminary efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors with confirmed…
- Conditions
- Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder
- Trial name
- NCT06090318
- Testing
- Milademetan, Atezolizumab
- Sponsor
- Rain Oncology Inc
Angiokeratomas, Chronic Kidney Disease
Biomarker for Patients With Fabry Disease (BioFabry)
Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood
- Conditions
- Angiokeratomas, Chronic Kidney Disease, Ocular Abnormalities, Hearing Loss
- Trial name
- BioFabry (NCT02778295)
- Where
- 3 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Miscarriage, Recurrent
Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score
Recurrent pregnancy loss (RPL) is a clinical problem affecting 1-5% of couples of reproductive age. The contribution of thrombophilia to RPL is disputed.
- Trial name
- TiC-RPL (NCT03336463)
- Where
- 8 sites in Spain, United Kingdom
- Volunteers
- 364 people
- Sponsor
- Ferrer inCode, S.L.
Early Pregnancy Loss
Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss
The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.
- Trial name
- NCT04935138
- Testing
- cfDNA analysis
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Quest Diagnostics-Nichols Insitute
Heavy Menstrual Bleeding
Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial
This study is designed as an open label, single-arm, decentralized research study in which patients with idiopathic heavy menstrual bleeding will receive transcutaneous auricular neurostimulation (tAN), which targets the…
- Trial name
- NCT06814028
- Testing
- Volta System
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Spark Biomedical, Inc.
Recurrent Pregnancy Loss, Recurrent Miscarriage
A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)
This is a randomised, double blind, multi-center, placebo-controlled study of subcutaneous NT100 in pregnant women with a history of unexplained recurrent pregnancy loss.
- Trial name
- RESPONSE (NCT02156063)
- Testing
- NT100
- Where
- 19 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Nora Therapeutics, Inc.
Medical Abortion
Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion
National multi-center non interventional study aiming at investigating the effectiveness and safety of the combination mifepristone-misoprostol prescribed in Canada to women for medical termination of pregnancy at or before 63…
- Trial name
- MiMAC (NCT04905251)
- Testing
- Mifepristone-Misoprostol
- Where
- 6 sites in Canada
- Volunteers
- 129 people
- Sponsor
- Linepharma International LTD
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
Weight Reduction
Avoiding Diabetes After Pregnancy Trial
The Avoiding Diabetes After Pregnancy Trial (ADAPT) study was designed to test the effectiveness of interventions that potentially increase the adoption of Diabetes Prevention Program (DPP) elements by women who had a pregnancy…
- Trial name
- ADAPT (NCT01923350)
- Testing
- Weight Reduction Intervention, Weight Reduction Control Arm, Tested for diabetes
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Social & Scientific Systems Inc.
Menorrhagia, Heavy Menstrual Bleeding
Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss
The objective of this study is to evaluate the safety and effectiveness of the endometrial ablation device Librata in reducing menstrual blood loss at 12 months post-treatment when used in pre-menopausal women with menorrhagia…
- Trial name
- LEADER (NCT03725306)
- Testing
- Librata
- Volunteers
- 200 people
- Sponsor
- LiNA Medical
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Pregnancy
Correlation Between PIF Maternal Serum Levels and Pregnancy Outcome
PIF: biomarker of pregnancy, miscarriage, premature birth, preeclampsia, placenta accreta. Except for serum hCG, no pregnancy-complication markers are widely employed to predict the need for medical intervention.
- Trial name
- PIFBlood1 (NCT01805102)
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 500 people
- Sponsor
- BioIncept LLC